302 related articles for article (PubMed ID: 12084774)
1. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
[TBL] [Abstract][Full Text] [Related]
2. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
[TBL] [Abstract][Full Text] [Related]
3. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
[TBL] [Abstract][Full Text] [Related]
4. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues.
Liu H; Atkins J; Kass RS
J Gen Physiol; 2003 Mar; 121(3):199-214. PubMed ID: 12601084
[TBL] [Abstract][Full Text] [Related]
5. Mutations in cardiac sodium channels: clinical implications.
Liu H; Clancy C; Cormier J; Kass R
Am J Pharmacogenomics; 2003; 3(3):173-9. PubMed ID: 12814325
[TBL] [Abstract][Full Text] [Related]
6. State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide.
Wang GK; Russell C; Wang SY
J Gen Physiol; 2003 Sep; 122(3):365-74. PubMed ID: 12913091
[TBL] [Abstract][Full Text] [Related]
7. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome.
Kambouris NG; Nuss HB; Johns DC; Marbán E; Tomaselli GF; Balser JR
J Clin Invest; 2000 Apr; 105(8):1133-40. PubMed ID: 10772658
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
9. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Nagatomo T; January CT; Makielski JC
Mol Pharmacol; 2000 Jan; 57(1):101-7. PubMed ID: 10617684
[TBL] [Abstract][Full Text] [Related]
10. Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block.
Zhu Y; Kyle JW; Lee PJ
Am J Physiol Heart Circ Physiol; 2006 Jul; 291(1):H29-37. PubMed ID: 16501012
[TBL] [Abstract][Full Text] [Related]
11. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs.
Valdivia CR; Tester DJ; Rok BA; Porter CB; Munger TM; Jahangir A; Makielski JC; Ackerman MJ
Cardiovasc Res; 2004 Apr; 62(1):53-62. PubMed ID: 15023552
[TBL] [Abstract][Full Text] [Related]
12. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
[TBL] [Abstract][Full Text] [Related]
13. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
Makita N; Behr E; Shimizu W; Horie M; Sunami A; Crotti L; Schulze-Bahr E; Fukuhara S; Mochizuki N; Makiyama T; Itoh H; Christiansen M; McKeown P; Miyamoto K; Kamakura S; Tsutsui H; Schwartz PJ; George AL; Roden DM
J Clin Invest; 2008 Jun; 118(6):2219-29. PubMed ID: 18451998
[TBL] [Abstract][Full Text] [Related]
14. State-dependent trapping of flecainide in the cardiac sodium channel.
Ramos E; O'leary ME
J Physiol; 2004 Oct; 560(Pt 1):37-49. PubMed ID: 15272045
[TBL] [Abstract][Full Text] [Related]
15. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
[TBL] [Abstract][Full Text] [Related]
16. A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.
Bankston JR; Yue M; Chung W; Spyres M; Pass RH; Silver E; Sampson KJ; Kass RS
PLoS One; 2007 Dec; 2(12):e1258. PubMed ID: 18060054
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
Shimizu W; Antzelevitch C; Suyama K; Kurita T; Taguchi A; Aihara N; Takaki H; Sunagawa K; Kamakura S
J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1320-9. PubMed ID: 11196553
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
[TBL] [Abstract][Full Text] [Related]
19. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes.
Rivolta I; Abriel H; Tateyama M; Liu H; Memmi M; Vardas P; Napolitano C; Priori SG; Kass RS
J Biol Chem; 2001 Aug; 276(33):30623-30. PubMed ID: 11410597
[TBL] [Abstract][Full Text] [Related]
20. A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation.
Keller DI; Acharfi S; Delacrétaz E; Benammar N; Rotter M; Pfammatter JP; Fressart V; Guicheney P; Chahine M
J Mol Cell Cardiol; 2003 Dec; 35(12):1513-21. PubMed ID: 14654377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
